Healthcare

The European Commission granted orphan designation following a positive opinion from the European Medicines Agency’s Committee for Orphan Medicinal Products. SGT-212 also holds Fast Track, Orphan Drug and Rare Pediatric Disease designations from the U.S. Food and Drug Administration.

The new study is an early feasibility investigation assessing clinical safety and device functionality, including direct Bluetooth communication. Freedom combines implantable sensing technology with an integrated battery and wireless communication capabilities.

Amanat Acquisition Corp (NASDAQ:AMAN), a special purpose acquisition company, and Corxel Pharmaceuticals, Inc. (Corxel US) announced on 26 October 2026 a definitive business combination agreement to create a publicly listed, obesity-focused biopharmaceutical company. The combined company is expected to be listed on the Nasdaq …

Bristol Myers Squibb (NYSE:BMY) and SystImmune announced on 26 October 2026 positive results from a prespecified interim analysis of the Phase 3 PANKU-Lung01 study of izalontamab brengitecan (iza-bren) in previously treated EGFR-mutated non-squamous non-small cell lung cancer (NSCLC). The data were reported by SystImmune's …

Can-Fite BioPharma Ltd. presented final data from its Phase IIa study of namodenoson in advanced pancreatic ductal adenocarcinoma at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid on 26 October 2026. The Israeli biotechnology company reported that the study achieved its …

HUTCHMED (China) Limited (NASDAQ:HCM) announced on 26 October 2026 positive results from the SANOVO Phase III trial in China, presented at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid. The trial tested ORPATHYS (savolitinib) plus TAGRISSO (osimertinib) against TAGRISSO alone in …

Actinogen Medical (ASX:ACW) announced on 26 October 2026 that it received a research and development tax incentive (RDTI) rebate of $10,838,793, including interest, from the Australian Tax Office for the 2026 financial year. The payment arrives as the biotechnology company approaches topline results from …